利妥昔单抗治疗难治性/复发性血栓性血小板减少性紫癜的疗效与安全性
[Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura].
作者信息
Cui Jing, Zhu Tie-nan, Zou Nong, Chen Miao, Zhao Yong-qiang
机构信息
Department of Hematology, PUMC Hospital, CAMS and PUMC, Beijing, China.
出版信息
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Feb;35(1):116-20. doi: 10.3881/j.issn.1000-503X.2013.01.022.
OBJECTIVE
To evaluate the efficacy and safety of rituximab in treating patients with refractory and/or relapsing thrombotic thrombocytopenic purpura (TTP).
METHODS
Totally three patients received rituximab as salvage therapy in our hospital. Rituximab was administered at a weekly dose of 375 mg/m(2) for 2 or 4 consecutive weeks. After clinical remission, patients were followed up every 3 months.
RESULTS
All three patients achieved complete remission. The median time to platelet count recovery was 7 days (4-12 days) after the first rituximab infusion. During the follow-up (median: 12 months; range: 9-18 months), no patients experienced relapse. No side effect was noted during treatment and follow-up period.
CONCLUSION
Therapy with rituximab is effective and well tolerated for patients with refractory or relapsing TTP.
目的
评估利妥昔单抗治疗难治性和/或复发性血栓性血小板减少性紫癜（TTP）患者的疗效和安全性。
方法
我院共有3例患者接受利妥昔单抗作为挽救治疗。利妥昔单抗以每周375 mg/m²的剂量连续给药2或4周。临床缓解后，每3个月对患者进行随访。
结果
所有3例患者均实现完全缓解。首次输注利妥昔单抗后，血小板计数恢复的中位时间为7天（4 - 12天）。在随访期间（中位时间：12个月；范围：9 - 18个月），无患者复发。治疗及随访期间未观察到副作用。
结论
利妥昔单抗治疗难治性或复发性TTP患者有效且耐受性良好。
Zotero 插件